Deoxyribonucleic Acid (DNA) Read, Write and Edit Market Report 2025

The deoxyribonucleic acid (DNA) read, write, and edit market size has grown rapidly in recent years. It will grow from $8.65 billion in 2024 to $10.18 billion in 2025 at a compound annual growth rate (CAGR) of 17.7%. Growth during the historical period can be linked to the increasing prevalence of genetic disorders, the rising demand for personalized medicine, the expansion of academic and industrial genomics research, the growing adoption of next-generation sequencing, and the rise in government and private investments in sequencing infrastructure.

The deoxyribonucleic acid (DNA) read, write, and edit market size is expected to see rapid growth in the next few years. It will grow to $19.28 billion in 2029 at a compound annual growth rate (CAGR) of 17.3%. Growth in the forecast period can be attributed to the increasing demand for precision medicine, greater investment in DNA-based data storage, the rising adoption of synthetic biology, the expansion of DNA sequencing services, and heightened awareness of early disease detection. Key trends expected during the forecast period include technological progress in genome editing, continuous innovation in DNA synthesis methods, the development of portable sequencing devices, advancements in research and development, and improvements in bioinformatics tools.

The rising prevalence of genetic disorders is expected to drive the growth of the deoxyribonucleic acid (DNA) read, write, and edit market in the coming years. Genetic disorders are medical conditions caused by abnormalities in an individual's DNA, either inherited from one or both parents or resulting from new mutations. The increase in genetic disorders is linked to the rise in parental age, as older parents have a greater likelihood of passing genetic mutations to their children. DNA reading, writing, and editing technologies help manage genetic disorders by enabling accurate detection, correction, and modification of disease-causing genes. These advancements improve healthcare outcomes through targeted therapies, lowering the risk of inherited conditions, and advancing personalized medicine for affected individuals. For example, in May 2024, the National Health Service, a UK-based government department, reported that 17,000 people are living with sickle cell disease, an inherited genetic blood disorder, with approximately 250 new cases diagnosed annually. Therefore, the growing prevalence of genetic disorders is fueling the expansion of the DNA read, write, and edit market.

Companies in the DNA read, write, and edit market are emphasizing the development of advanced products, such as high-quality, regulatory-compliant synthetic DNA, to speed up research, ensure safety, and facilitate the commercialization of advanced therapies. Regulatory-compliant synthetic DNA refers to artificially produced DNA that is accurate, free from contaminants, and manufactured according to safety and legal standards, making it suitable for research, diagnostics, and therapeutic use. For instance, in May 2022, GenScript Inc., a US-based biotechnology company, introduced GenExact (GMP single-stranded DNA) and GenWand (GMP closed-end linear double-stranded DNA) services. These offerings support faster transitions from research and development to investigational new drug (IND) submissions and clinical trials by providing high-quality, non-viral homology-directed repair (HDR) templates, which enable safer and more efficient CRISPR non-viral gene insertion for advanced cell and gene therapies. The DNA is produced in specialized cGMP facilities, comes with full documentation and regulatory compliance, and undergoes rigorous testing to ensure identity, purity, potency, and safety, delivering a reliable and scalable source of genetic material for therapeutic purposes.

In January 2023, Qiagen N.V., a biotechnology company based in the Netherlands, acquired Verogen Inc. for an undisclosed amount. This acquisition enhanced Qiagen’s capabilities in DNA read, write, and edit technologies, strengthening its position in forensic genomics and molecular diagnostics markets. Verogen Inc. is a US-based biotechnology company specializing in DNA read, write, and edit technologies.

Major players in the deoxyribonucleic acid (DNA) read, write and edit market are Roche Holding AG, Bayer AG, Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., MGI Tech, Bio-Rad Laboratories Inc., BGI Group, Ginkgo Bioworks, Oxford Nanopore Technologies, Twist Bioscience Corporation, New England Biolabs, GenScript Biotech Corporation, Pacific Biosciences, Beam Therapeutics Inc., Prime Medicine, Editas Medicine Inc., Cellectis S.A., 3Billion Inc., and CRISPR Therapeutics AG.

North America was the largest region in the deoxyribonucleic acid (DNA) read, write and edit market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in deoxyribonucleic acid (DNA) read, write and edit market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the deoxyribonucleic acid (DNA) read, write and edit market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Deoxyribonucleic acid (DNA) reading, writing, and editing refer to a set of techniques used to sequence (read) genetic information, synthesize (write) new DNA strands, and modify (edit) existing genetic sequences. These processes aim to understand the genetic code, create synthetic genes, and enable precise genetic modifications for research, medicine, and biotechnology.

The primary categories of DNA reading, writing, and editing include kits and reagents, cell line engineering, animal models, and services. Kits and reagents consist of pre-packaged materials and chemical substances designed to perform specific laboratory tests, experiments, or procedures in research, diagnostics, and biotechnology. These utilize various technologies such as clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nucleases (TALEN), zinc finger nucleases, and others, with different delivery methods such as viral vectors, non-viral vectors, electroporation, and microinjection. Their applications cover gene therapy, diagnostics, biotechnology, agriculture, and synthetic biology, with major end users including pharmaceutical and biotechnology companies, academic and research institutions, and clinical research organizations.

The deoxyribonucleic acid (DNA) read, write, and edit market research report is one of a series of new reports that provides deoxyribonucleic acid (DNA) read, write, and edit market statistics, including the deoxyribonucleic acid (DNA) read, write, and edit industry global market size, regional shares, competitors with the deoxyribonucleic acid (DNA) read, write, and edit market share, detailed deoxyribonucleic acid (DNA) read, write, and edit market segments, market trends, and opportunities, and any further data you may need to thrive in the deoxyribonucleic acid (DNA) read, write, and edit industry. This deoxyribonucleic acid (DNA) read, write, and edit market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The deoxyribonucleic acid (DNA) read, write and edit market consists of revenues earned by entities by providing services such as genetic testing services, genome sequencing services, gene editing services, synthetic biology services, and bioinformatics analysis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The deoxyribonucleic acid (DNA) read, write and edit market also includes sales of deoxyribonucleic acid (DNA) sequencers, gene synthesis kits, genome editing tools, and bioinformatics software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.